Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Matulonis Highlights Novel Strategies, Emerging Agents in Ovarian Cancer

January 25th 2019

Ursula A. Matulonis, MD, highlights available and emerging treatment options and strategies for patients with recurrent ovarian cancer.

Dr. English on an Investigational Antibody-Drug Conjugate in Ovarian Cancer

January 25th 2019

Diana P. English, MD, a gynecologic oncologist at Stanford Hospital and Clinics, discusses an investigational antibody-drug conjugate (ADC) in ovarian cancer.

European Commission Approves Maintenance Rucaparib in Ovarian Cancer

January 25th 2019

The European Commission has approved an expanded indication for single-agent rucaparib as a maintenance therapy in adult patients with platinum-sensitive, relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, regardless of BRCA status.

Dr. Horowitz on Frontline Strategies in Newly Diagnosed Ovarian Cancer

January 24th 2019

Neil Horowitz, MD, director of Clinical Research in Gynecologic Oncology, assistant professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Dana-Farber Cancer Institute, discusses frontline strategies in the treatment of patients with newly diagnosed advanced ovarian cancer.

Immunotherapy Combos May Have Role in Ovarian Cancer

January 24th 2019

Panagiotis A. Konstantinopoulos, MD, discusses the status of immunotherapy in ovarian cancer and focuses on numerous combinations under investigation.

Ongoing Research to Move Needle Forward in Gynecologic Cancer Treatment

January 21st 2019

Robert Coleman, MD, highlights recent advances made in gynecologic cancers and provide insight into ongoing research to move the needle forward.

Dr. Coleman on Advances Made in Ovarian Cancer Treatment

January 20th 2019

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses advances made in the treatment of ovarian cancer.

Antiangiogenics, ADCs Still Have Roles in Ovarian Cancer Treatment

January 20th 2019

For all the positive data associated with PARP inhibitors in patients with epithelial ovarian cancer who have known BRCA mutations and despite several agents winning FDA approval over the past few years, PARP inhibitors aren’t curing patients.

Westin Highlights the Evolving Role of PARP Inhibitors in Ovarian Cancer

January 19th 2019

Shannon Westin, MD, discusses the evolving role of PARP inhibitors in ovarian cancer, novel investigational agents, and the importance of molecular testing.

Investigators Still Seeking Options Beyond PARP Inhibitors in Ovarian Cancer

January 19th 2019

Targeted therapy is effectively established as an option for patients with ovarian cancers. However, beyond PARP inhibition in the BRCA-mutated or homologous recombination deficient population, questions remain about how to best treat these patients.

Dr. Kurnit on Adjuvant Chemotherapy Regimens in Mucinous Ovarian Cancer

January 19th 2019

Katherine Kurnit, MD, OBGYN oncology fellow at the University of Texas MD Anderson Cancer Center, compares the benefit of gastrointestinal-based versus gynecologic-based adjuvant chemotherapy regimens in patients with mucinous ovarian cancer.

Adjuvant GI-Based Chemo Regimens Improve Survival in Mucinous Ovarian Cancer

January 19th 2019

Results from a recent retrospective study indicate that treatment with a gastrointestinal-based adjuvant chemotherapy regimen may be more beneficial than that of a gynecologic-based one in patients with mucinous ovarian cancer.

Genomic Testing Has Impact on Treatment Decisions in Ovarian Cancer

January 18th 2019

Genomic testing to guide treatment decisions for women with ovarian cancer is in its early days. However, as more platforms become commercially available, physicians will need to understand the similarities and differences between tests.

Dr. Westin on Advances Made With PARP Inhibitors in Ovarian Cancer

January 18th 2019

Shannon N. Westin, MD, MPH, associate professor, The University of Texas MD Anderson Cancer Center, discusses advances made with PARP inhibitors in the ovarian cancer treatment paradigm.

PARP Combos May Represent Future in Frontline Maintenance Ovarian Cancer Setting

January 18th 2019

Several ongoing trials are examining combinations of PARP inhibitors and immunotherapy agents as frontline maintenance for patients with ovarian cancer.

FDA Issues Letter Regarding Safety Concerns With Paclitaxel-Coated Devices

January 18th 2019

The FDA has issued a letter to healthcare providers that they should monitor patients with a type of peripheral arterial disease who have been treated with vascular balloons that were coated with paclitaxel or stents that release paclitaxel in the femoropopliteal artery in the leg.

Surgeon Discusses Frontline Standard in Newly Diagnosed Ovarian Cancer

January 17th 2019

Neil Horowitz, MD, discusses surgical options for patients with newly diagnosed ovarian cancer.

Dr. Konstantinopoulos on the Phase III Results of the JAVELIN 200 Trial in Ovarian Cancer

January 17th 2019

Panagiotis A. Konstantinopoulos, MD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the disappointing results of the JAVELIN 200 trial in ovarian cancer.

Reminder App With Postsurgery Instructions Well Received by Patients With Ovarian Cancer

January 12th 2019

Nearly 1 IN 5 women who undergoes ovarian cancer surgery is readmitted for complications, but a web-based app may improve patient monitoring so complications and adverse events can be addressed quickly by the patient’s care team.

Expert Explains Evolving Options in Frontline Ovarian Cancer

January 12th 2019

Joyce F. Liu, MD, MPH, highlights the recent changes in the newly diagnosed ovarian cancer space and what the oncology field could see by the end of 2019.